Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients - 13/01/18
Funding sources: Dr Liu received funding support from the Yale University Medical Student Research Fellowship. Dr King received funding support from The Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research. |
|
Conflicts of interest: Dr King has served on advisory boards or as consultant for Aclaris Therapeutics Inc, Celgene, Concert Pharmaceuticals Inc, Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals, and Roivant Sciences Ltd. Other authors have no conflicts of interest to report. |
Vol 78 - N° 2
P. 403 - février 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?